Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression

Lancet

Volumn 349, Issue 9053, 1997, Pages 701-702

  Mirza, Darius F ^b   Gunson, Bridget K ^a   Soonawalla, Zahir ^a   Pirenne, Jacques ^a   Mayer, A David ^a   Buckels, John A C ^a   McMaster, Paul ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031038215     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60138-9     Document Type: Article

References (4)

1. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion based formulation (Neoral). Drugs 1995; 50: 924-41.
2. Hubscher SG. Pathology of liver allograft rejection. Transpl Immunol 1994; 2: 118-23.
3. Candinas D, Gunson BK, Nightingale P, Hubscher S, McMaster P, Neuberger JM. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet 1995; 346: 1117-21.
4. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-28.